Human red blood cell acetylcholinesterase activity: a revisit after fifteen years.

Human red blood cell acetylcholinesterase (RBC-AChE) activity is valuable for detecting potential exposure to cholinesterase inhibiting substances (CIS). A reliable population-based RBC-AChE activity reference range is critical for early and massive clinical and occupational toxicology screening. Previous published studies were often limited to small numbers of subjects, various testing methods, and crude statistical data analyses. We tested 4818 adult subjects with a well-established 17-minute modified Michel method over a 2-year period. We conducted a retrospective data analysis and systematically investigated on the influences to testing values from gender, age, age group, and their combinations and interactions. No significant difference was observed in the testing values between males (mean, medium, interquartile range = 0.76, 0.76, 0.71-0.80 ΔpH/h, respectively) and females (mean, medium, interquartile range = 0.76, 0.76, 0.71-0.81 ΔpH/hour, respectively), when gender was the only factor considered (p = 0.7238). However, with age progression, male testing values exhibited a consistent upward trend, while females did not show any clear patterns. Linear regression analysis of the data revealed that gender, age, and age group more or less affected testing values either as independent variables or with their combinations and interactions. However, more potential factors need to be included to achieve better testing value predictions. We recommend the toxicological testing community to adopt a new set of age group specific RBC-AChE activity reference ranges for males (0.68-0.80, 0.69-0.81, 0.70-0.83, 0.71-0.84, and 0.73-0.87 ΔpH/h for 18-29, 30-39, 40-49, 50-59, and ≥60 years old, respectively) while keeping the current reference range (0.63-0.89 ΔpH/hour) for females.

The four most frequently diagnosed vector-borne diseases among service member and non-service member beneficiaries in the geographic combatant commands, 2010-2022.

Vector-borne diseases (VBDs) may pose an increased risk for U.S. service members during recurring military training exercises, operations, and response missions, in addition to residence in endemic regions within and outside the continental U.S. Prior MSMR reports address VBD surveillance, described by surveillance data for 23 reportable medical events (RMEs), among active duty and reserve component service members. This report covers a 13-year surveillance period, from January 2010 to December 2022, and provides linear trends of selected VBDs among Armed Forces service and non-service member beneficiaries diagnosed at installations within the Northern Command (NORTHCOM), Africa Command (AFRICOM), Central Command (CENTCOM), European Command (EUCOM), Indo-Pacific Command (INDOPACOM), or Southern Command (SOUTHCOM). Trends of only the 4 mostfrequently reported VBDs were evaluated, as Lyme disease, malaria, Rocky Mountain Spotted Fever (RMSF), and dengue fever comprised 90% (n=5,199) of all 23 VBDs (n=5,750) among Military Health System (MHS) beneficiaries documented as RMEs during the surveillance period.

A Hidden Gem: Highlighting the Indispensable Capabilities and History of the DoD Cholinesterase Monitoring Program and DoD Cholinesterase Reference Laboratory.

The DoD Cholinesterase Monitoring Program and Cholinesterase Reference Laboratory have safeguarded U.S. government employees in chemical defense for over five decades. Considering Russia's potential deployment of chemical warfare nerve agents in Ukraine, it is critical to maintain a robust cholinesterase testing program and its efficiency presently and in future.

Myopericarditis Associated With Smallpox Vaccination Among US Army Personnel - Fort Hood, Texas, 2018.

OBJECTIVE: In March 2018, the US Department of Defense (DOD) added the smallpox vaccination, using ACAM2000, to its routine immunizations, increasing the number of persons receiving the vaccine. The following month, Fort Hood reported a cluster of 5 myopericarditis cases. The Centers for Disease Control and Prevention and the DOD launched an investigation. METHODS: The investigation consisted of a review of medical records, establishment of case definitions, causality assessment, patient interviews, and active surveillance. A 2-sided exact rate ratio test was used to compare myopericarditis incidence rates. RESULTS: This investigation identified 4 cases of probable myopericarditis and 1 case of suspected myopericarditis. No alternative etiology was identified as a cause. No additional cases were identified. There was no statistically significant difference in incidence rates between the observed cluster (5.23 per 1000 vaccinated individuals, 95% CI: 1.7-12.2) and the ACAM2000 clinical trial outcomes for symptomatic persons, which was 2.29 per 1000 vaccinated individuals (95% CI: 0.3-8.3). CONCLUSIONS: Vaccination with ACAM2000 is the presumptive cause of this cluster. Caution should be exercised before considering vaccination campaigns for smallpox given the clinical morbidity and costs incurred by a case of myopericarditis. Risk of myopericarditis should be carefully weighed with risk of exposure to smallpox.

Surveillance of spotted fever rickettsioses at Army installations in the U.S. Central and Atlantic regions, 2012-2018.

Spotted fever rickettsioses (SFR) are emerging in the Atlantic and Central regions of the U.S., though cases have been reported across the contiguous U.S. Military populations may be at increased risk for SFR because of residence in these regions and frequent field training in tick habitats. Surveillance for Rocky Mountain spotted fever in the Army began in 1998 and was expanded to include all SFR in 2017. Between 2016 and 2017, the rate of active component cases reported from Army installations in the Atlantic and Central regions of the U.S. increased nearly five-fold from 2016 (0.55 per 100,000 person-years [p-yrs]) to 2017 (2.65 per 100,000 p-yrs). The majority of SFR cases were reported from Fort Leonard Wood, MO, and Fort Bragg, NC. Most reported cases had no documented symptoms consistent with SFR and could not be confirmed as "cases" by standard case-defining methods. SFR surveillance and control efforts in military populations can be improved by better adherence to guidelines for SFR diagnosis and through the use of available advanced laboratory techniques.

Cases of Coronavirus Disease 2019 and Comorbidities Among Military Health System Beneficiaries, 1 January 2020 through 30 September 2020.

The U.S. Secretary of Health and Human Services declared a public health emergency in the U.S. on 31 January 2020 in response to the spread of coronavirus disease 2019 (COVID-19). On 20 March 2020, the President of the U.S. proclaimed that the COVID-19 outbreak in the U.S. constituted a national emergency, retroactive to 1 March 2020. Between 1 January and 30 September 2020, a total of 53,048 Military Health System (MHS) beneficiaries were identified as confirmed or probable cases of COVID-19 infection. The majority of cases were male (69.1%) and 45.4% were aged 20-29 years. The demographic and clinical characteristics of these cases varied by beneficiary type (active component service members, recruits, Reserve/Guard, dependents, retirees, and cadets). Of the total cases, 35.8% had been diagnosed with at least 1 of the comorbidities of interest, and 20.0% had been diagnosed with 2 or more comorbidities. The most common comorbidities present in COVID-19 cases were any cardiovascular diseases(12.7%), obesity or overweight (11.1%), metabolic diseases (10.5%), hypertension (9.9%), neoplasms (7.9%), any lung diseases (7.5%), substance use disorders, including nicotine dependence (5.4%), and asthma (3.2%). There were a total of 1,803 hospitalizations (3.4%) and 84 deaths (0.2%).

Case report: Possible psittacosis in a military family member-clinical and public health management issues in military settings.

Chlamydia psittaci infection among humans (psittacosis) and pet birds (avian chlamydiosis), also known as parrot disease, parrot fever, and ornithosis, is a zoonotic bacterial disease. Humans most often become infected by inhaling the organism when urine, respiratory secretions, or dried feces of infected birds are dispersed in the air as very fine droplets or dust particles. C. psittaci infection of humans can cause influenza-like symptoms, such as fever of abrupt onset, pronounced headache, and dry cough, and can lead to severe pneumonia and non-respiratory health problems. Infection can also be asymptomatic. There is no vaccine for this infection. The disease is treatable with a tetracycline antibiotic, usually doxycycline, or a second-line therapy such as erythromycin or azithromycin. With appropriate treatment, the infection is rarely fatal. This report describes a case of severe, community-acquired pneumonia possibly due to C. psittaci in a resident of Colorado and examines significant clinical and epidemiological characteristics of psittacosis that affect confirming the diagnosis and managing the risks of exposure to psittacine (parrot-type) birds.

Expedited Partner Therapy to Combat Neisseria gonorrhoeae and Chlamydia trachomatis in Military Populations: Can We Apply This Best Practice?

Expedited Partner Therapy (EPT) is the practice of treating the partners of patients with sexually transmitted infections by providing medications for the patient to deliver to his or her sexual partner (s) without direct clinical assessment of the partner(s). EPT is an evidence-based option that can augment existing partner management strategies. For military health care providers, questions still loom as to the pragmatic medical, legal, and ethical uncertainties of EPT use in military populations. These issues, in addition to the absence of an explicit Department of Defense EPT policy may dissuade military clinicians from fully employing EPT to prevent reinfection and inhibit additional disease transmission in their patients. To advance the notion that EPT could not only be an efficient but also a vital measure to decrease the high sexually transmitted disease burden, this report highlights existing approaches utilized by military providers to treat partners of patients diagnosed with chlamydia and/or gonorrhea, benefits of using EPT in military populations, and specific challenges of implementing an EPT program. This report asserts that now is the time to "push the conversation" on the use of EPT as a viable choice for military providers.